Mezzion Pharma Co., Ltd.

As of March 31, 2026, Mezzion Pharma Co., Ltd. carries a market capitalization of 2.63T, placing it among publicly traded companies globally. Its enterprise value stands at 2.63T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Mezzion Pharma Co., Ltd. has 30.39M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 327.85, and the price-to-book ratio stands at 169.68.

These figures are as of March 31, 2026. The EV/Sales ratio of 329.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.63T versus a market cap of 2.63T, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Mezzion Pharma Co., Ltd. maintains a current ratio of 0.47, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 80.08, indicating elevated leverage, while an interest coverage ratio of -8.02 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Mezzion Pharma Co., Ltd. posted a negative return on equity (ROE) of -125.67, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -43.51, reflecting losses generated across the asset base. The company generates approximately 442.88M in revenue per employee across its workforce of 18.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.22 indicates how many times Mezzion Pharma Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Mezzion Pharma Co., Ltd. recorded an income tax benefit of -3.91B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -40.84B and -36.93B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Mezzion Pharma Co., Ltd.'s stock has gained approximately 1.59% over the past 52 weeks. The 50-day moving average sits at 67,446.00, while the 200-day moving average is 84,158.00.

Over the twelve months ended March 31, 2026, Mezzion Pharma Co., Ltd. generated 7.97B in revenue and converted that into -36.93B in net income, yielding earnings per share of -1,223.61. EBITDA reached -16.89B, while operating income came in at -17.81B.

As of March 31, 2026, Mezzion Pharma Co., Ltd. holds 17.42B in cash and equivalents against 12.42B in total debt, resulting in a net debt position of -6.86B. Total book value stands at 15.51B, with working capital of -43.95B providing operational flexibility.

Mezzion Pharma Co., Ltd. produced -18.95B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -11.93B in capital expenditures, free cash flow totaled -30.89B - equivalent to -1,023.39 per share.

Over the twelve months ended March 31, 2026, Mezzion Pharma Co., Ltd. posted a gross margin of 18.23, reflecting its pricing power and cost economics. The operating margin of -223.45 and net profit margin of -463.23 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -1.18: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.03, meaning Mezzion Pharma Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Mezzion Pharma Co., Ltd.'s most recent stock split took place on April 5, 2022 with a 1:3 split ratio.

As of March 31, 2026, Mezzion Pharma Co., Ltd. has an Altman Z-Score of 10.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.